PointState Capital’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

PointState Capital’s Portfolio OTLKW Stock Details OTLKW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100,000	Closed	-$10K	–	153
2021 Q4	$10K	Hold	100,000	–	–	﹤0.01%	116
2021 Q3	$20K	Hold	100,000	–	–	﹤0.01%	136
2021 Q2	$32K	Hold	100,000	–	–	﹤0.01%	125
2021 Q1	$101K	Hold	100,000	–	–	﹤0.01%	116
2020 Q4	$22K	Hold	100,000	–	–	﹤0.01%	127
2020 Q3	$12K	Hold	100,000	–	–	﹤0.01%	103
2020 Q2	$26K	Hold	100,000	–	–	﹤0.01%	84
2020 Q1	$16K	Hold	100,000	–	–	﹤0.01%	64
2019 Q4	$8K	Hold	100,000	–	–	﹤0.01%	105
2019 Q3	$12K	Hold	100,000	–	–	﹤0.01%	106
2019 Q2	$11K	Hold	100,000	–	–	﹤0.01%	109
2019 Q1	$35K	Hold	100,000	–	–	﹤0.01%	123
2018 Q4	$12K	Buy	+100,000	New	+$12.6K	﹤0.01%	84

PointState Capital's OTLKW Position: Q1 2022 in Review

PointState Capital sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q1 2022, closing a stake of 100,000 shares — an estimated $10K sold.

PointState Capital first reported a position in OTLKW in Q4 2018 and held it in 13 quarters. The position peaked at $101K in Q1 2021. 0 funds tracked by Wall St. Rank hold OTLKW as of Q1 2022.

PointState Capital reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 100,000 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q1 2022, an estimated $10K.
PointState Capital first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q4 2018 and held it in 13 quarters.
PointState Capital's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $101K in Q1 2021.
0 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.